Recovered coronavirus patients’ plasma could cure others…

Dr. Ian Lipkin the Director for the Center for Infection and Immunity at Columbia University went on Lou Dobbs tonight to talk about how the plasma from Coronavirus patients that have been cured could be used to treat new patients. If you don’t know already, plasma is a yellowish liquid part of the blood that carries cells and proteins throughout the body.

We found that during the Spanish flu pandemic of 1918, medical literature described how transfusions of blood products from survivors could have contributed to a 50% reduction in death among patients who were severely ill. The same type of cures happened during a school outbreak of measles in 1934, which only 3 of the 62 students treated with the plasma of cured patients developed measles. The three infected only had mild cases. This type of plasma therapy was also recently used as treatment during the outbreaks of Ebola and avian flu.

Watch the clip where Dr. Lipkin describes the research and possibility of treatment:

BIG NEWS: Dr. Ian Lipkin says plasma from recovered Cornavirus patients may be an effective treatment to save lives. #AmericaFirst #KAG2020 #Dobbs pic.twitter.com/pXGIblnkPH

— Lou Dobbs (@LouDobbs) March 12, 2020

It turns out that over the past few weeks, China has been using this technique on new coronavirus patients. Here are a few videos:

With Dr. Lipkin’s remarks and these video’s it seems like this treatment could be a viable option to combat this pandemic. In fact when researching this topic, we noticed that Japanese company Takeda Pharmaceutical announced last week that it is currently testing it as well:

From MarketWatch:

The Japanese drugmaker said March 4 it plans to test hyperimmune globulins for people who are at high risk for infection. As part of its research, which will be performed in Georgia, Takeda said it would need access to plasma from people who have recovered from COVID-19 or those who have received a vaccine if one is developed. Dr. Rajeev Venkayya, president of Takeda’s vaccine business, is the co-lead of the company’s COVID-19 response team. Like J&J, Takeda plans to examine whether other therapies, both experimental or with regulatory approval, may have treatment potential.

So while there aren’t any concrete studies of this with the covid-19, it seems like there is some hope with treatment for those that may come in contact with it.

If you appreciate this article, make sure you help share it.